The relationship between glycated haemoglobin and blood glucose‐lowering treatment trajectories in type 2 diabetes: The Fremantle Diabetes Study Phase II

Aims To examine the relationships between glycaemia and treatment complexity over 6 years in well‐characterized community‐based people with type 2 diabetes. Materials and Methods Fremantle Diabetes Study Phase II participants who had type 2 diabetes with glycated haemoglobin (HbA1c) and blood glucose‐lowering therapy (BGLT) data over 6 years were included. Group‐based multi‐trajectory modelling identified combined HbA1c/BGLT trajectory subgroups for diabetes durations of ≤1.0 year (Group 1; n = 160), >1.0 to 10.0 years (Group 2; n = 382;) and >10.0 years (Group 3; n = 357). Multinomial regression was used to identify baseline associates of subgroup membership. Results The optimum numbers of trajectory subgroups were three in Group 1 (low, medium, high) and four in Groups 2 and 3 (low, low/high medium, high). Each low trajectory subgroup maintained a mean HbA1c concentration of